Sean M Hughes1, Urvashi Pandey1, Christine Johnston2,3, Jeanne Marrazzo4, Florian Hladik1,2,3, Elizabeth Micks1. 1. Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA. 2. Department of Medicine, University of Washington, Seattle, Washington, USA. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
PROBLEM: Changes in sex hormones during the menstrual cycle and contraceptive vaginal ring (CVR) use influence immunity within the female genital tract, but the magnitude of these effects and their anatomical location are unclear. METHOD OF STUDY: In a prospective study, 29 women were assessed at three-time points: follicular phase, luteal phase, and one month after initiation of the ethinyl estradiol/etonogestrel CVR (NuvaRing®, Merck). We performed microarrays on endocervical cytobrushes and measured immune mediators in cervicovaginal fluid, adjusting for bacterial vaginosis and the presence of blood. We compared these results to public gene expression data from the fallopian tubes, endometrium, endo- and ectocervix, and vagina. RESULTS: Immune-related gene expression in the endocervix and immune mediators in cervicovaginal fluid increased during CVR use versus both menstrual phases, and in the follicular versus luteal phase. The antimicrobial protein granulysin was high during CVR use, intermediate in the follicular phase, and nearly absent from the luteal phase. Re-analysis of public gene expression data confirmed increased immune-related gene expression in the endocervix during the follicular phase. However, in the fallopian tube, endometrium, and vagina, the follicular phase showed immunosuppression. CONCLUSIONS: Immune-related genes in the cervicovaginal tract were highest during CVR use, intermediate in the follicular phase, and lowest in the luteal phase. Granulysin is a potential biomarker of menstrual phase: Frequently detected in follicular samples, but rare in luteal. Lastly, immunological differences between the follicular and luteal phases vary throughout the female genital tract.
PROBLEM: Changes in sex hormones during the menstrual cycle and contraceptive vaginal ring (CVR) use influence immunity within the female genital tract, but the magnitude of these effects and their anatomical location are unclear. METHOD OF STUDY: In a prospective study, 29 women were assessed at three-time points: follicular phase, luteal phase, and one month after initiation of the ethinyl estradiol/etonogestrel CVR (NuvaRing®, Merck). We performed microarrays on endocervical cytobrushes and measured immune mediators in cervicovaginal fluid, adjusting for bacterial vaginosis and the presence of blood. We compared these results to public gene expression data from the fallopian tubes, endometrium, endo- and ectocervix, and vagina. RESULTS: Immune-related gene expression in the endocervix and immune mediators in cervicovaginal fluid increased during CVR use versus both menstrual phases, and in the follicular versus luteal phase. The antimicrobial protein granulysin was high during CVR use, intermediate in the follicular phase, and nearly absent from the luteal phase. Re-analysis of public gene expression data confirmed increased immune-related gene expression in the endocervix during the follicular phase. However, in the fallopian tube, endometrium, and vagina, the follicular phase showed immunosuppression. CONCLUSIONS: Immune-related genes in the cervicovaginal tract were highest during CVR use, intermediate in the follicular phase, and lowest in the luteal phase. Granulysin is a potential biomarker of menstrual phase: Frequently detected in follicular samples, but rare in luteal. Lastly, immunological differences between the follicular and luteal phases vary throughout the female genital tract.
Authors: Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Irina Zalenskaya; Thomas Kimble; Susana Asin; Christiane Rollenhagen; Sharon M Anderson; Betsy Herold; Pedro M M Mesquita; Nicola Richardson-Harman; Tina Cunningham; Jill L Schwartz; Gustavo F Doncel Journal: AIDS Res Hum Retroviruses Date: 2016-02-10 Impact factor: 2.205
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Jocelyn M Wessels; Julie Lajoie; Maeve I J Hay Cooper; Kenneth Omollo; Allison M Felker; Danielle Vitali; Haley A Dupont; Philip V Nguyen; Kristen Mueller; Fatemeh Vahedi; Joshua Kimani; Julius Oyugi; Juliana Cheruiyot; John N Mungai; Alexandre Deshiere; Michel J Tremblay; Tony Mazzulli; Jennifer C Stearns; Ali A Ashkar; Keith R Fowke; Michael G Surette; Charu Kaushic Journal: Dis Model Mech Date: 2019-10-23 Impact factor: 5.758
Authors: Sean M Hughes; Claire N Levy; Ronit Katz; Erica M Lokken; Melis N Anahtar; Melissa Barousse Hall; Frideborg Bradley; Philip E Castle; Valerie Cortez; Gustavo F Doncel; Raina Fichorova; Paul L Fidel; Keith R Fowke; Suzanna C Francis; Mimi Ghosh; Loris Y Hwang; Mariel Jais; Vicky Jespers; Vineet Joag; Rupert Kaul; Jordan Kyongo; Timothy Lahey; Huiying Li; Julia Makinde; Lyle R McKinnon; Anna-Barbara Moscicki; Richard M Novak; Mickey V Patel; Intira Sriprasert; Andrea R Thurman; Sergey Yegorov; Nelly Rwamba Mugo; Alison C Roxby; Elizabeth Micks; Florian Hladik Journal: BMC Med Date: 2022-10-05 Impact factor: 11.150